IP Verse

Scalable Lentiviral Vector Production System Compatible With Industrial Pharmaceutical Applications - EP2782997

The patent EP2782997 was granted to Genethon on Jan 10, 2018. The application was originally filed on Nov 26, 2012 under application number EP12795778A. The patent is currently recorded with a legal status of "Revoked".

EP2782997

GENETHON
Application Number
EP12795778A
Filing Date
Nov 26, 2012
Status
Revoked
May 20, 2022
Grant Date
Jan 10, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (8)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEOct 10, 2018HOFFMANN EITLEADMISSIBLE
JAMES POOLEOct 10, 2018CARPMAELS & RANSFORDADMISSIBLE
PATENTANWALTE ISENBRUCK BOSL HORSCHLER PARTG MBBOct 10, 2018LAHRTZADMISSIBLE
RICKEROct 10, 2018OETKEADMISSIBLE
STRAWMANOct 10, 2018CMS CAMERON MCKENNA NABARRO OLSWANGADMISSIBLE
MILTENYI BIOTECOct 9, 2018KISTERSADMISSIBLE
GLAXOSMITHKLINEOct 4, 2018KIMADMISSIBLE
OXFORD BIOMEDICA UKOct 4, 2018D YOUNGADMISSIBLE

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0770140
DESCRIPTIONUS6013240
OPPOSITIONUS2011008894
OPPOSITIONUS2012171724
OPPOSITIONUS6210922
OPPOSITIONWO02077202
OPPOSITIONWO03039459
OPPOSITIONWO2009153563
OPPOSITIONWO2011012725
OPPOSITIONWO2011097447
OPPOSITIONWO2013076309

Non-Patent Literature (NPL) Citations (98) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- H P Lesch ET AL, "Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors", Gene Therapy, GB, (20110120), vol. 18, no. 6, doi:10.1038/gt.2010.162, ISSN 0969-7128, pages 531 - 538, XP055339732
OPPOSITION- "Adaptation of a Prosavin(R) producer cell line to suspension culture", The 6th BSGT Annual Conference, (20090421), XP055523321-
OPPOSITION- Ansorge, "Development of a scalable process for lentiviral vector mass production by transient transfection (thesis)", UNIVERSITÉ DE MONTRÉAL, CA, (20100600), pages 1 - 302, URL: https://publications.polymtl.ca/323/1/2010_SvenAnsorge.pdf, XP055503623-
OPPOSITION- AUSUBEL L. J. et al., "312. Large Scale Lentiviral Vector Production in a GMP Facility", Molecular Therapy, (20070000), vol. 15, no. Suppl. 1, page S118, XP055523199-
OPPOSITION- "BIOSTAT® CultiBag STR Plus 50L", Sartorius stedim biotech, (20090900), pages 1 - 6, XP055523236-
OPPOSITION- "BIOSTAT® STR True scaleability in single-use", Sartorius stedim biotech, (20120418), pages 1 - 12, URL: https://www.sartoriusglobal.com/mediafile/Broch_BIOSTAT_CultiBagSTR_SBI1509-e.pdf, XP055523406-
OPPOSITION- BRADY et al., "675. Development, Scale-Up and Technology Transfer for Rapid, Automated, cGMP Compliant, Large-Volume Suspension Cell Based Process for Lentiviral Vector Production", Molecular Therapy, (20100000), vol. 18, pages S263 - S264, XP055523203-
OPPOSITION- BRADY J. et al., "675. Development, Scale-Up and Technology Transfer for Rapid, Automated, cGMP Compliant, Large-Volume Suspension Cell Based Process for Lentiviral Vector Production", Molecular Therapy, (20100000), vol. 18, no. 1, pages S263 - S264, XP055523203-
OPPOSITION- CHANG et al., "Lentiviral vectors. Preparation and use", CHANG et al., Morgen Jeffrey R., GENE THERAPY PROTOCOLS, (20020000), vol. 69, pages 303 - 318, XP055522928-
OPPOSITION- "CultiBag STR", Sartorius steim biotech, (20090900), pages 1 - 5, XP055523229-
OPPOSITION- "Cultivation of HEK 293 cells in suspension using WAVE Bioreactor systems 2/10 and 20/50 (Procedure 28-9308-80 AA)", WAVE Bioreactor Systems, (20030000), pages 1 - 3, XP055523227-
OPPOSITION- "Disposable CellbagTM bioreactors for WAVE BioreactorTM systems (data file 28.9511-36 AE)", GE Healthcare, (20120400), pages 1 - 8, XP055523219-
OPPOSITION- DUBRIDGE et al., "Analysis of Mutation in Human Cells by Using an Epstein-Barr Virus Shuttle System", Molecular and Cellular Biology, (19870000), vol. 7, pages 379 - 387, XP008135455-
OPPOSITION- GAMA-NORTON et al., "Lentivirus Production Is Influenced by SV 40 Large T- Antigen and Chromosomal Integration of the Vector in HEK293 Cells", Human gene therapy, (20110000), vol. 22, pages 1269 - 1279, XP055525003-
OPPOSITION- GASMI et al., J Gen Virol., vol. 73, no. 3, pages 1828 - 1834, XP000974541-
OPPOSITION- GASMI et al., "Requirements for Efficient Production and Transduction of Hu- man Immunodeficiency Virus Type 1-Based Vectors", Journal of virology, (19990000), vol. 73, no. 3, pages 1828 - 1834, XP000974541-
OPPOSITION- GASMI et al., "Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors.", Journal of Virology, (19990300), vol. 73, pages 1828 - 1834, XP000974541-
OPPOSITION- "Growth and Maintenance of the 293FTZ Cell Line (Catalog nos. R700-07)", Invitrogen by life technologies, (20100714), pages 1 - 12, XP055525249-
OPPOSITION- Laura STEVENSON et al., "Adaptation of a ProSavin® Producer Cell Line to Suspension Culture", The 6th BSGT Annual Conference, (20090421), XP055523321-
OPPOSITION- Maurizio Federico, Lentivirus Gene Engineering Protocols Second Edition, Humana Press, pages FP - 228-
OPPOSITION- MIYOSHI et al., "Development of a Self-Inactivating Lentivirus Vector", J Virol, (19980000), vol. 72, pages 8150 - 8157, XP000886313-
OPPOSITION- PARKER C. V. et al., "P219 Development of a HEK293T clonal suspension cell line for the production of High titre EIAV lentiviral vector", Human Gene Therapy, (20111000), vol. 22, page A39, A106, XP055523179-
OPPOSITION- Parker C V; Mitrophanous And H J Stewart K A, "P219 Development of a HEK293T clonal suspension cell line for the production of High titre EIAV lentiviral vector", Human Gene Therapy (Poster Abstracts), (20111000), vol. 22, page A39, A106, XP055523179-
OPPOSITION- PARKER et al., "Development of a HEK293T clonal suspension cell line for the production of high titre EIAV lentiviral vector", 19th Annual Congress of the European Society for Gene and Cell Therapy (ESGCT, Brighton, UK, (20111027), XP055522918-
OPPOSITION- PARKER et al., "Development of a HEK293T clonal suspension cell line for the production of high titre EIAV lentiviral vector", (20110000), XP055522918-
OPPOSITION- PARKER et al., "Development of a HEK293T clonal suspension cell line for the production of high titre EIAV lentiviral vector'', P219, presented at the conference", European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress 2011, Brighton, UK-
OPPOSITION- Parker; Et Al, "Development of a HEK293T Clonal Suspension Cell line :or the Production of High Titre EIAV lentiviral Vector", British Society for Gene Therapy Collaborative Congress, (2011), page 1, XP055522918-
OPPOSITION- PARKER et al., "Development of a HEK293T Clonal Suspension Cell line:or the Production of High Titre EIAV lentiviral Vector", Conference Proceedings: European Society of Cell & Gene Therapy British Society for Gene Therapy Collaborative Congress, (20111027), XP055522918-
OPPOSITION- PARKER et al., "European Society of Gene and Cell Therapy - British Society of Gene and Cell Therapy Collaborative Congress", British Society of Gene and Cell Therapy, (20111027), page P219, XP055525024-
OPPOSITION- PARKER et al., "P219 Development of a HEK293T clonal suspension cell line for the production of high titre EIAV lentiviral vector", HUMAN GENE THERAPY, (20111022), page A106, (20111018), XP055523179-
OPPOSITION- Parker et al., "P219 Development of a HEK293T clonal suspension cell line for the production of High titre EIAV lentiviral vector", Human Gene Therapy (Poster Abstracts), (20111000), vol. 22, page A39, A106, XP055523179-
OPPOSITION- PEAR et al., "Production of high-titer helper-free retroviruses by transient transfection", PNAS, (19930000), vol. 90, pages 8392 - 8396, XP001345299-
OPPOSITION- RODRIGUES et al., "2 Production of Retroviral and Lentiviral Gene Therapy Vectors: Challenges in the Manufacturing of Lipid Enveloped Virus", RODRIGUES et al., Ke XU, Viral Gene Therapy, IntechOpen, (20110700), pages 1 - 40, ISBN 978-953-307-539-6, XP055523381-
OPPOSITION- SEGURA et al., "New Protocol for Lentiviral Vector Mass Production", Lentivirus Gene Engineering Protocols, (20091119), vol. 614, pages 39 - 52, XP009185305-
OPPOSITION- SEGURA et al., "Production of Lentiviral Vectors by Large-Scale Transient Transfection of Suspension Cultures and Affinity Chromatography Purifica- tion", Biotechnology and Bioengineering, (20070000), vol. 98, no. 4, pages 789 - 799, XP055525005-
OPPOSITION- SEGURA M. M. et al., "New protocol for lentiviral vector mass production", Methods in Molecular Biology (Methods and Protocols, Totowa, NJ, vol. 614, pages 39 - 52, XP009185305-
OPPOSITION- "Serum-free and suspension adaptation for 293 cells 12-765Q Pro293â„¢s-CDMâ„¢ Medium 12-764Q Pro293â„¢a-CDMâ„¢ Medium", Lonza, (20110000), pages 1 - 2, XP055523308-
OPPOSITION- SONEOKA et al., "A TRANSIENT THREE-PLASMID EXPRESSION SYSTEM FOR THE PRODUCTION OF HIGH TITER RETROVIRAL VECTORS", Nucleic Acids Research, (19950000), vol. 23, pages 628 - 633, XP000569533-
OPPOSITION- STEVENSON et al., "Adaptation of a Prosavin(R) producer cell line to suspension culture", The 6th BSGT Annual Conference, (20090421), XP055523321-
OPPOSITION- "The pMHC array demonstrates that untouched T cell populations from Acute Myeloid Leukaemia patients can recognize tumour antigens", Human Gene Therapy, (20110000), vol. 22, no. 10, pages A39 - A106, XP055524989-
OPPOSITION- TONINI et al., "Transient production of retroviral- and lentiviral-based vectors for the transduction of Mammalian cells", Cell Cycle Control and Dysregulation Protocols, (20040000), vol. 18, pages 141 - 148, XP055522933-
OPPOSITION- TONINI et al., "Transient Production of Retroviral and Lentiviral-based Vectors for the Transduction of Mammalian Cells", Methods in Molecular Biology, vol. 285, pages 141 - 148, XP055525255-
OPPOSITION- TUVESSON et al., "Development of a generic transient transfection process at 100 L scale", Cytotechnology, (20080000), vol. 56, pages 123 - 136, XP019571616-
OPPOSITION- XING et al., "Scale-Up Analysis for a CHO Cell Culture Process in Large-Scale Bioreactors", Biotechnology and Bioengineering, (20090209), vol. 103, pages 733 - 746, XP055523586-
OPPOSITION- ZUFFEREY, R et al., Production of lentiviral vectors. Lentiviral vectors, (20020000), pages 107 - 121, XP009053528-
OPPOSITION- YANG et al., "Fed-batch bioreactor process scale-up from 3-L to 2,500-L scale for monoclonal antibody production from cell culture.", Biotechnology and Bioengineering, (20070309), vol. 98, pages 141 - 154, XP055523581
OPPOSITION- SEGURA et al., "Production of Lentiviral Vectors by Large-Scale Transient Transfection of Suspension Cultures and Affinity Chromatography Purification", Biotech. Bioeng., vol. 98, no. 4, pages 789 - 799, XP055023183
OPPOSITION- SEGURA et al., "Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification", Biotechnology and Bioengineering, (20070000), vol. 98, no. 4, pages 789 - 799, XP055023183
OPPOSITION- SEGURA M. M. et al., "Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification", Biotechnology and Bioengineering, (20070000), vol. 98, no. 4, pages 789 - 799, XP055023183
OPPOSITION- ANSORGE et al., "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures", J Gene Med, (20090000), vol. 11, pages 868 - 876, XP002689780
OPPOSITION- ANSORGE et al., "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures", J Gene Med., vol. 11, pages 868 - 876, XP002689780
OPPOSITION- ANSORGE et al., "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures", The journal of gene medicine, (20090000), vol. 11, no. 10, pages 868 - 876, XP002689780
OPPOSITION- ANSORGE et al., "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures", The Journal of Gene Medicine, (20090000), vol. 11, pages 868 - 876, XP002689780
OPPOSITION- ANSORGE et al., "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension culture s", THE JOURNAL OF GENE MEDICINE, J Gene Med, (20090000), vol. 11, pages 868 - 876, XP002689780
OPPOSITION- ANSORGE S. et al., "Development of a scalable process for high-yield lentiviral vector production by transient transfection of HEK293 suspension cultures", The Journal of Gene Medicine, (20090000), vol. 11, no. 10, pages 868 - 876, XP002689780
OPPOSITION- GERAERTS et al., "Upscaling of Lentiviral Vector Production by Tangential Flow Filtration", The Journal of Gene Medicine, (20050000), vol. 7, doi:10.1002/jgm.778, pages 1299 - 1310, XP002542493
OPPOSITION- CHOOSAKOONKRIANG et al., "American Chemical Society and American Pharmaceutical Association", Journal of Pharmaceutical Sciences, (20030000), vol. 92, no. 8, pages 1710 - 1722, XP055023366
OPPOSITION- CHOOSAKOONKRIANG et al., "Biophysical characterization of PEI/DNA complexes", J Pharm Sci., vol. 92, no. 8, pages 1710 - 1722, XP055023366
OPPOSITION- CHOOSAKOONKRIANG S. et al., "Biophysical characterization of PEI/DNA complexes", Journal of Pharmaceutical Sciences, (20030000), vol. 92, no. 8, pages 1710 - 1722, XP055023366
OPPOSITION- SAKODA et al., "A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes.", Journal of Molecular and Cellular Cardiololgy, (19991100), vol. 31, pages 2037 - 2047, XP000971848
OPPOSITION- TOLEDO et al., "Polyethylenimine-Based Transfection Method as a Simple and Effective Way to Produce Recombinant Lentiviral Vectors", Appl Biochem Biotechnol, (20090000), vol. 157, pages 538 - 544, XP055523370
OPPOSITION- ANSORGE S. et al., "Recent progress in lentiviral vector mass production", Biochemical Engineering Journal, (20100000), vol. 48, pages 362 - 377, XP002664830
OPPOSITION- SENA-ESTEVES et al., "Optimized large-scale production of high titer lentivirus vector pseudotypes", Journal of Virological Methods, (20040000), vol. 122, pages 131 - 139, XP004637751
OPPOSITION- KURODA et al., "Simplified Lentivirus Vector Production in Protein-free Media using Polyethylenimine-mediated Transfection", Journal of Virological Methods, (20090000), vol. 157, doi:10.1016/j.jviromet.2008.11.021, pages 113 - 121, XP026064560
OPPOSITION- KURODA et al., "Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection", Journal of Virological Methods, (20090000), vol. 157, pages 113 - 121, XP026064560
OPPOSITION- KURODA et al., "Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection", Journal of Virological Methods, (20090120), vol. 157, pages 113 - 121, XP026064560
OPPOSITION- KOH et al., "Delivery of Polyethylenimine/DNA Complexes Assembled in a Microfluidics Device", Mol Pharm, (20090000), vol. 6, pages 1333 - 1342, XP055523434
OPPOSITION- VARLEY et al., "Reactor design for large scale suspension animal cell culture", Cytotechnology, (19990000), vol. 29, pages 177 - 205, XP019236596
OPPOSITION- MARKS, "Equipment design considerations for large scale cell culture", Cytotechnology, (20030000), vol. 42, pages 21 - 33, XP019236784
OPPOSITION- STEWART et al., "Development of inducible EIAV-based lentiviral vector packaging and producer cell lines", Gene Therapy, (20090000), vol. 16, no. 6, pages 805 - 814, XP055434092
OPPOSITION- STEWART et al., "Development of inducible EIA V-based lentiviral vector packaging and producer cell lines", Gene Therapy, (20090000), vol. 16, pages 805 - 814, XP055434092
OPPOSITION- LESCH et al., "Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors", Gene Therapy, (20110000), vol. 18, no. 6, pages 531 - 538, XP055339732
OPPOSITION- LESCH et al., "Production and purification of lentiviral vectors generated in 293T suspension cells with baculoviral vectors", Gene Therapy, (20110000), vol. 18, pages 531 - 538, XP055339732
OPPOSITION- LESCH et al., "Production and purification of lentiviral vectors generated in293T suspension cells with baculoviral vectors", Gene Therapy, vol. 18, pages 531 - 538, XP055339732
OPPOSITION- BROUSSAU S. et al., "Inducible Packaging Cells for Large-scale Production of Lentiviral Vectors in Serum-free Suspension Culture", Molecular Therapy, (20080000), vol. 16, no. 3, pages 500 - 507, XP055387760
OPPOSITION- KAROLEWSKI et al., "Comparison of Transfection Conditions for a Lentivirus Vector Produced in Large Volumes", Human Gene Therapy, (20030920), vol. 14, pages 1287 - 1296, XP055523574
OPPOSITION- Laura Stevenson; Mitrophanos And P A Radcliffe K A, "P7 Adaptation of a Prosavin producer cell line to suspension culture (BSGT 2009 Poster Presentations)", HUMAN GENE THERAPY, (20090401), page 396, 398, XP055523334
OPPOSITION- STEVENSON et al., "Adaptation of a Prosavin producer cell line to suspension culture (BSGT 2009 Poster Presentations)", HUMAN GENE THERAPY, (20090400), vol. 20, page 396, 398, XP055523334
OPPOSITION- STEVENSON et al., "P7 Adaptation of a Prosavin producer cell line to suspension culture (BSGT 2009 Poster Presentations)", HUMAN GENE THERAPY, (20090400), page 396,398, XP055523334
OPPOSITION- MERTEN et al., "Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application", Human Gene Therapy, (20110300), vol. 22, doi:10.1089/hum.2010.060, pages 343 - 356, XP055023182
OPPOSITION- MERTEN et al., "Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application", Human Gene Therapy, (20110300), vol. 22, no. 3, pages 343 - 356, XP055023182
OPPOSITION- MERTEN et al., "Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application", Human Gene Therapy, (20110300), vol. 22, pages 343 - 356, XP055023182
OPPOSITION- MERTEN et al., "Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application", HUMAN GENE THERAPY, (20110300), vol. 22, pages 343 - 356, XP055023182
OPPOSITION- MERTEN O.-W. et al., "Large-Scale Manufacture and Characterization of a Lentiviral Vector Produced for Clinical Ex Vivo Gene Therapy Application", Human Gene Therapy, (20110300), vol. 22, pages 343 - 356, XP055023182
OPPOSITION- STEWART et al., "A Stable Producer Cell Line for the Manufacture of a Lentiviral Vector for Gene Therapy of Parkinson's Disease", Human Gene Therapy, (20110000), vol. 22, pages 357 - 369, XP055337365
OPPOSITION- STEWART et al., "A Stable Producer Cell Line for the Manufacture of a Lentiviral Vector for Gene Therapy of Parkinson's Disease", HUMAN GENE THERAPY, (20110300), vol. 22, pages 357 - 369, XP055337365
OPPOSITION- WITTING et al., "Efficient Large Volume Lentiviral Vector Production Using Flow Electroporation", Human Gene Therapy, (20110920), vol. 23, pages 243 - 249, XP055143670
OPPOSITION- WITTING et al., "Efficient Large Volume Lentiviral Vector Production Using Flow Electroporation", Human Gene Therapy, (20120000), vol. 23, pages 243 - 249, XP055143670
OPPOSITION- WITTING et al., Hum Gene Ther., (20110920), vol. 23, no. 2, pages 243 - 249, XP055143670
OPPOSITION- ARICESCU et al., "A time- and cost-efficient system for high-level protein production in mammalian cells", Acta Cryst, (20060000), vol. 62, no. 10, pages 1243 - 1250, XP055208379
OPPOSITION- JAALOUK et al., "Inhibition of histone deacetylation in 293GPG packaging cell line improves the production of self-inactivating MLV-derived retroviral vectors", Virology Journal, (20060000), vol. 3, pages 1 - 12, XP021019331
OPPOSITION- YUAN et al., "The Scattered Twelve Tribes of HEK293", Biomedical & Pharmacology Journal, (20180600), vol. 11, no. 2, pages 621 - 623, XP055523593
OPPOSITION- HALDANKAR et al., "Serum-Free Suspension Large-Scale Transient Transfection of CHO Cells in WAVE Bioreactors", Molecular Biotechnology, (20060000), vol. 34, pages 191 - 199, XP055606624
OPPOSITION- PHAM P. L. et al., "Large-Scale Transfection of Mammalian Cells for the Fast Production of Recombinant Protein", Molecular Biotechnology, (20060000), vol. 34, pages 225 - 237, XP055068367
OPPOSITION- SCHWEIZER et al., Curr Gene Ther., vol. 10, pages 474 - 486, XP009154493
OPPOSITION- SCHWEIZER et al., "Large-Scale Production Means for the Manufacturing of Lentiviral Vectors", Current Gene Therapy, (20100000), vol. 10, no. 6, pages 474 - 486, XP009154493
OPPOSITION- SCHWEIZER et al., "Large-scale production means for the manufacturing of lentiviral vectors", Current Gene Therapy, (20101200), vol. 10, no. 6, pages 474 - 486, XP009154493
OPPOSITION- SCHWEIZER M. et al., "Large-scale production means for the manufacturing of lentiviral vectors", Current Gene Therapy, (20101200), vol. 10, no. 6, pages 474 - 486, XP009154493

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents